CANCER GENETICS, INC.

(CGIX)
Delayed Nasdaq  -  04/12 04:00:01 pm EDT
3.710 USD   -7.71%
05/16Cancer Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
03/30Cancer Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
2021CANCER GENETICS : Vyant Bio Presentation – April 2021
PU
SummaryQuotesChartsNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Cancer Genetics : Vyant Bio Presentation – April 2021

04/06/2021 | 04:04pm EDT

Human First Drug

Discovery

Integrating Novel Human

Spheroid Biology & Data

Science Technologies with

IND-Enabling Expertise

Company Presentation Q1 2021

S A F E H A R B O R

Additional Information about the Proposed Merger and Where to Find It

In connection with the proposed Merger between Cancer Genetics ("CGIX") and StemoniX (the "Merger"), CGIX and StemoniX filed relevant materials with the Securities and Exchange

Commission, or the SEC, including a registration statement on Form S-4 that contains a prospectus and a proxy statement. INVESTORS AND SECURITY HOLDERS OF CGIX AND STEMONIX ARE URGED TO READ THESE MATERIALS (AS WELL AS AMENDMENTS AND SUPPLEMENTS THERETO AND ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN) BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT CGIX, STEMONIX AND THE PROPOSED MERGER. The proxy statement, prospectus and other relevant materials, and any other documents filed by CGIX with the SEC, may be obtained free of charge at the SEC website at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by CGIX by directing a written request to: Cancer Genetics, Inc., c/o John A. Roberts, Chief Executive Officer, 201 Route 17 North 2nd Floor, Rutherford, NJ 07070.

These slides shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities in connection with the proposed Merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Participants in the Solicitation

CGIX and its directors and executive officers and StemoniX and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of CGIX in connection with the proposed transaction under the rules of the SEC. Information about the directors and executive officers of CGIX and their ownership of shares of CGIX's common stock is set forth in its Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on May 29, 2020, and in subsequent documents to be filed with the SEC, including the Registration Statement referred to above. Additional information regarding the persons who may be deemed participants in the proxy solicitations and a description of their direct and indirect interests in the proposed merger, by security holdings or otherwise, are included in the Registration Statement and other relevant materials filed with the SEC. These documents are available free of charge at the SEC web site (www.sec.gov) and from the Chief Executive Officer at CGIX at the address described above.

Forward Looking Statements:

These slides contain Forward-looking statements which involve risks and uncertainties, including, without limitation, risks inherent in our ability to satisfy all closing conditions to the merger with StemoniX, Inc. and realize the expected benefits therefrom, our attempts to adapt to the global coronavirus pandemic, our attempts to achieve profitability by increasing sales of our pre-clinical services, maintain our existing customer base and avoid cancellation of customer contracts or discontinuance of trials, our attempts to raise capital to meet our liquidity needs, market and other conditions, and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2019, Form 10-Q for the quarter ended September 30, 2020, and the Form S-4, as amended, referred to above along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

2

VISION

Focus on the transformation of our business strategy to participate as a disruptor in therapeutic discovery

Our approach includes partnering with biotech and pharma to

identify unique therapeutics through the integration of novel

human biology with AI driven data science, engineering and regulatory expertise

3

DRUG DISCOVERY

DEFINING A

Needs A Disruption

New Approach

Widely used models for predicting drug efficacy

DATA SCIENCE capabilities bring human data to the

& safety have underperformed

EARLIEST stages of the R&D process and OPTIMIZE

THERAPEUTIC EFFICACY & SAFETY

Human biology is introduced late in the R&D

StemoniX has created HIGHLY FUNCTIONAL

process resulting in high failure rates & costs

HUMAN spheroids (organ-like models) at SCALE

Human neurosphere with oscillating neural network

4

Strategic Value Proposition

Human-First Drug Discovery Engine:

StemoniX

Discovery

CGIX-vivoPharm

Engine

Industrialized Human

Cancer Big Data

Spheroids (Discovery)

Tumor Line Library

Data Science

Global Partners

Machine Learning

Efficacy & Safety Data

Global Pharma

Late Stage

Partners

Preclinical Experts

in vivo Research

Vertically Integrated Development

World-leading human spheroid technology is predictive of success. Biology- and AI-enabled Data Science Seasoned in vivo Expertise

Global Partnership Footprint

Leading Pharma Partners

Validated Human Model Platforms

Trusted Pre-clinical & Regulatory Capabilities

Multi-shot on Goal Drug Discovery

High-Throughput Human

Pre-clinical Screening

Modality Convergence (Novel In Vitro Biology + Software + In Vivo)

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Vyant Bio Inc. published this content on 06 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 April 2021 20:03:02 UTC.


© Publicnow 2021
All news about CANCER GENETICS, INC.
05/16Cancer Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 20..
CI
03/30Cancer Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 202..
CI
2021CANCER GENETICS : Vyant Bio Presentation – April 2021
PU
2021Cancer Genetics and StemoniX Announce Merger Closing
GL
2021CANCER GENETICS : Management's Discussion and Analysis of Financial Condition and Results ..
AQ
2021Cancer Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 202..
CI
2021Cancer Genetics, Inc. has Changed its Ticker to VYNT from CGIX
CI
2021Cancer Genetics, Inc. has Changed its Name to Vyant Bio, Inc
CI
2021CANCER GENETICS, INC.(NASDAQCM : CGIX) dropped from NASDAQ Composite Index
CI
2021StemoniX Inc. completed the acquisition of Cancer Genetics, Inc. from a group of shareh..
CI
More news
Chart CANCER GENETICS, INC.
Duration : Period :
Cancer Genetics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart